EBSCO Logo
Connecting you to content on EBSCOhost
Title

Clinical significance of 2-[F]fluoro-2-deoxy- d-glucose positron emission tomography for the assessment of I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma.

Authors

Nakazawa, Azusa; Higuchi, Tetsuya; Oriuchi, Noboru; Arisaka, Yukiko; Endo, Keigo

Abstract

Purpose: The aim of this study was to evaluate the significance of 2-[F]fluoro-2-deoxy- d-glucose (FDG) positron emission tomography (PET) in the assessment of the therapeutic response to I-metaiodobenzylguanidine (MIBG) in malignant phaeochromocytoma. Methods: We reviewed the records of 11 patients (7 men and 4 women) with malignant phaeochromocytoma who underwent I-MIBG therapy (100-200 mCi). F-FDG PET and serum catecholamine assays were performed 3 months before and after the first dose of I-MIBG. FDG uptake was evaluated in the observed lesions using the maximum standardised uptake value (SUV). The average SUV of all lesions (ASUV) was calculated. If more than five lesions were identified, the average SUV of the five highest SUV (ASUV5) was calculated. The ratio of pre- and post-therapy values was calculated for the highest SUV (rMSUV), ASUV (rASUV), ASUV5 (rASUV5), CT diameter (rCT) and serum catecholamine (rCA). Responder (R) and non-responder (NR) groups were defined after a clinical follow-up of at least 6 months according to changes in symptoms, CT, magnetic resonance imaging (MRI) and I-MIBG scan. Results: Post-therapy evaluation revealed five R and six NR patients. The size of the target lesions was not significantly different before and after therapy ( p > 0.05). However, ASUV and ASUV5 were significantly lower in the R group (rASUV 0.64 ± 0.18, rASUV5 0.68 ± 0.17) compared to the NR group (rASUV 1.40 ± 0.54, rASUV5 1.37 ± 0.61) ( p < 0.05). Conclusion: F-FDG PET can be potentially used to evaluate the response of malignant phaeochromocytoma to I-MIBG therapy.

Subjects

PHEOCHROMOCYTOMA; POSITRON emission tomography; RADIOISOTOPES; CATECHOLAMINES; CHROMAFFIN cells

Publication

European Journal of Nuclear Medicine & Molecular Imaging, 2011, Vol 38, Issue 10, p1869

ISSN

1619-7070

Publication type

Academic Journal

DOI

10.1007/s00259-011-1872-3

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved